ANTX Stock Summary and Trading Ideas (An2 Therapeutics | NASDAQ:ANTX)

AN2 Therapeutics Inc is a biopharmaceutical company focused on discovering and developing novel small molecule therapeutics derived from its boron chemistry platform. The company has a pipeline of boron-based compounds in development for Chagas disease, non-tuberculous mycobacterial (NTM) and melioidosis, along with early-stage programs focused on targets in infectious diseases and oncology. Product candidate AN2-502998 Epetraborole.

An2 Therapeutics trades on the NASDAQ stock market under the symbol ANTX.

As of October 9, 2026, ANTX stock price declined to $4.40 with 428,532 million shares trading.

ANTX has a beta of -1.23, meaning it tends to be less sensitive to market movements. ANTX has a correlation of 0.01 to the broad based SPY ETF.

ANTX has a market cap of $166.04 million. This is considered a Micro Cap stock.

In the last 3 years, ANTX traded as high as $22.22 and as low as $.87.

The top ETF exchange traded funds that ANTX belongs to (by Net Assets): VTI, IWM, VXF, IWN, VTWO.

ANTX has outperformed the market in the last year with a return of +241.1%, while the SPY ETF gained +16.8%. However, in the most recent history, ANTX shares have underperformed the stock market with its stock returning -0.2% in the last 3 month period and -10.0% for the last 2 week period, while SPY has returned +4.7% and +1.5%, respectively.

ANTX support price is $4.43 and resistance is $4.93 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that ANTX shares will trade within this expected range on the day.